Construction and validation of a practical prognostic index for patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2401-2408

  Yamamoto, Noboru ^b   Watanabe, Toru ^a   Katsumata, Noriyuki ^b   Omuro, Yasushi ^b   Ando, Masashi ^b   Fukuda, Haruhiko ^b   Tokue, Yutaka ^b   Narabayashi, Masaru ^b   Adachi, Isamu ^b   Takashima, Shigemitsu ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; VALIDATION PROCESS;

EID: 0031830823     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2401     Document Type: Article

References (47)

1. Kakizoe T, Nakamura Y, Segami K, et al: Cancer Statistics in Japan. Tokyo, Japan, Foundation for Promotion of Cancer Research, 1997, pp 36-47
2. Goldhirsch A, Wood WC, Senn HJ, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441-1445, 1995
3. Osborne CK: Prognostic factors for breast cancer: Have they met their promise? J Clin Oncol 10:679-682, 1992
4. Neville AM, Bettelheim R, Gelber RD, et al: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 10:696-705, 1992
5. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989
6. Moon TE, Jones SE, Bonadonna G, et al: Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol 10:396-403, 1987
7. Lin PP, Allison DC, Wainstock J, et al: Impact of axillary lymph node dissection no the therapy of breast cancer patients. J Clin Oncol 11:1536-1544, 1993
8. McGuire WL, Tandon AK, Allred DC, et al: Treatment decisions in axillary node-negative breast cancer patients. J Natl Cancer Inst Monogr 11:173-180, 1992
9. Rosen PP, Groshen S, Kinne DW, et al: Factors influencing prognosis in node negative breast carcinoma: Analysis of 767 T1N0M0/ T2N0M0 patients with long term follow-up. J Clin Oncol 11:2090-2100, 1993
10. Tandon AK, Clark GM, Chamness GC, et al: Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297-302, 1990
11. Winstanley JH, Leinster SJ, Cooke TG, et al: Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 67:767-772, 1993
12. Tetu B, Brisson J, Cote C, et al: Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: An immunohistochemical study. Int J Cancer 55:429-435, 1993
13. Clark GM, Mathieu MC, Owens MA, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992
14. Stal O, Dufmats M, Hatschek T, et al: S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 11:1717-1722, 1993
15. Thor AD, Moore DI, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
16. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
17. Toikkanen S, Helin H, Isola J, et al: Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol 10:1044-1048, 1992
18. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
19. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
20. Venturini M, Bruzzi P, Mastro DL, et al: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 14:764-773, 1996
21. Valagussa P, Tess JDT, Rossi A, et al: Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes. Breast Cancer Res Treat 1:349-356, 1982
22. Swenerton KD, Legha SS, Smith T, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552-1562, 1979
23. Hortobagyi GN, Smith TL, Legha SS, et al: Multivariate analysis of prognostic factors of metastatic breast cancer. J Clin Oncol 1:776-786, 1983
24. Clark GM, Sledge GW Jr, Osborne CK, et al: survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55-61, 1987
25. Cutler SJ, Ardyce AJ, Taylor SG, et al: Classification of patients with disseminated cancer of the breast. Cancer 24:861-869, 1969
26. Blanco G, Hollf K, Heikkin M, et al: Prognostic factors in recurrent breast cancer: Relationship to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 62:142-146, 1990
27. Fey MF, Brunner KW, Sonntag RW: Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4:237-247, 1981
28. DiStefano A, Yong YY, Hortobagyi GN, et al: The natural history of breast cancer patients with brain metastases. Cancer 44:1913-1918, 1979
29. Zinser JW, Hortobagyi GN, Buzdar AU, et al: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5:773-782, 1987
30. Hietanen P, Miettinen M, Makinen J: Survival after first recurrence in breast cancer. Eur J Cancer Clin Oncol 22:913-919, 1986
31. Sledge GJ: Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer. J Clin Oncol 14:2191-2193, 1996
32. Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205, 1996
33. Watanabe T, Adachi I, Tajima K, et al: Improving the quality of life during chemoendocrine therapy for metastatic breast cancer: A randomized comparison of tamoxifen (TAM) versus medroxyprogesterone acetate (MPA) in combination with doxorubicin (ADM) plus cyclophosphamide (CPA). Proc Am Soc Clin Oncol 13:72, 1994 (abstr 90)
34. Hayward JL, Carbone PP, Henson JC, et al: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289-1294, 1977
35. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
36. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
37. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-200, 1972
38. Howell A, Barnes DM, Harland RN, et al: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1:588-591, 1984
39. Howat JM, Harris M, Swindell R, et al: The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 51:263-270, 1985
40. Stewart JF, King RJ, Sexton SA, et al: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17:449-453, 1981
41. Lonn U, Lonn S, Nilsson B, et al: Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy. Cancer 77:107-112, 1996
42. Goldie JH: Drug resistance and cancer chemotherapy strategy in breast cancer. Breast Cancer Res Treat 3:129-136, 1983
43. Robertson JF, Dixon AR, Nicholson RI, et al: Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 22:221-227, 1992
44. Campbell FC, Blarney RW, Elston CW, et al: Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer 44:456-459, 1981
45. Shinkai T, Eguchi K, Sasaki Y, et al: A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 30:1-6, 1992
46. Rawson NS, Peto J: An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 61:597-604, 1990
47. Anonymous: A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993